Shoreline Biosciences Wins a Comprehensive Summary Judgment Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
September 7, 2023, SAN DIEGO – Shoreline Biosciences, Inc., a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNKs) and macrophages (iMACs), today announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California. [Read more…]